Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/136657

Título:	Oral administration of a new HRI activator as a new strategy to improve high-fat-died-induced glucose intolerance, hepatic steatosis and hypertriglyceridemia through FGF21
Autor/a:	Zarei, Mohammad; Pujol Bech, Eugènia; Quesada López, Tania Paloma; Villarroya i Gombau, Francesc; Barroso Fernández, Emma; Vázquez Cruz, Santiago; Pizarro Delgado, Javier; Palomer Tarridas, Francesc Xavier; Vázquez Carrera, Manuel
Otros autores:	Universitat de Barcelona
Abstract:	BACKGROUND AND PURPOSE Fibroblast growth factor 21 (FGF21) has emerged as a therapeutic strategy for treating type 2 diabetes mellitus due to its antidiabetic effects, and this has led to the development of FGF21 longacting analogs. These compounds have some limitations, including requiring subcutaneous injection and their prolonged pharmacodynamic effect compared with native FGF21, which might be responsible for their reported side effects. EXPERIMENTAL APPROACH We have previously demonstrated that intraperitoneal administration of heme-regulated eukaryotic translation initiation factor 2α (eIF2α) kinase (HRI) activators increases hepatic and circulating levels of FGF21. In this study, we examined the effects of oral administration of a new HRI activator, EPB-53, on high-fat diet (HFD)-induced glucose intolerance, hepatic steatosis, and hypertriglyceridemia, compared with metformin. KEY RESULTS Administration of EPB-53 administration for the last two weeks, to mice fed a HFD for 10 weeks, reduced body weight gain, improved glucose intolerance, and prevented hepatic steatosis and hypertriglyceridemia; whereas metformin only ameliorated glucose intolerance. Moreover, EPB- 53, similarly to the reported effects of FGF21, reduced lipogenesis in cultured human hepatocytes and in the liver of mice fed a HFD. Administration of EPB-53 to Fgf21-knockout mice had no effects, demonstrating that its efficacy is dependent on this hormone. CONCLUSIONS AND IMPLICATIONS Overall, the findings of this study demonstrate that oral administration of HRI activators is a promising strategy for the treatment of type 2 diabetes mellitus and non-alcoholic fatty liver disease by increasing FGF21.
Materia(s):	-Malalties del fetge -Diabetis -Terapèutica -Liver diseases -Diabetes -Therapeutics
Derechos:	(c) The British Pharmacological Society, 2019 info:eu-repo/semantics/embargoedAccess
Tipo de documento:	Artículo Artículo - Versión aceptada
Editor:	Blackwell
Compartir:

Mostrar el registro completo del ítem